Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

CapCure Unlocking Immunotherapy Potential with CapCure: A Novel Chemical Antagonist of PSME4

Coordinator
Weizmann Institute of Science, Israel
Runs
1 August 2026 to 31 January 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335588

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy has transformed cancer treatment, yet many patients fail to benefit because their tumors develop intrinsic mechanisms to block immune attack. Recent discoveries from our ERC-funded work revealed that the proteasome, a central protein degradation system, can be hijacked by tumors to suppress immune recognition and promote an immunosuppressive environment. This Proof of Concept project aims to translate these findings into a novel therapeutic approach.

We will develop and validate small molecules that block this tumor-associated mechanism, restoring the ability of the immune system to detect and eliminate cancer cells. Our focus will be on two major cancers with a high unmet need, non–small cell lung cancer and aggressive breast cancer, where resistance to immunotherapy remains a critical challenge. The project will combine the development of a small molecule which will allow us to modulate proteasomes activity, together with preclinical validation, and a commercialization pathway including intellectual property protection and market analysis.

By the end of the project, we expect to deliver optimized drug candidates and a biomarker-guided framework to identify patients most likely to benefit. Ultimately, this work seeks to establish a new therapeutic class that enhances the effectiveness of existing immunotherapies, with the long-term goal of improving outcomes for patients whose cancers currently remain resistant to treatment.

Topics

Who is involved

OrganisationCityCountryRole
Weizmann Institute of ScienceRehovotIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI